Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer

Meera Nanjundan, Yasuhisa Nakayama, Wa Cheng Kwai, John Lahad, Jinsong Liu, Karen Lu, Wen Lin Kuo, Karen Smith-McCune, David Fishman, Joe Gray, Gordon Mills

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Increased copy number involving chromosome 3q26 is a frequent and early event in cancers of the ovary, lung, head and neck, cervix, and BRCA1 positive and basal breast cancers. The p110α catalytic subunit of phosphoinositide-3-kinase (PI3KCA) and protein kinase Cι (PKCι) have previously been shown as functionally deregulated by 3q copy number increase. High-resolution array comparative genomic hybridization of 235 high-grade serous epithelial ovarian cancers using contiguous bacterial artificial chromosomes across 3q26 delineated an ∼2 Mb-wide region at 3q26.2 encompassing PDCD10 to MYNN (chr3:168722613-170908630). Ecotropic viral integration site-1 (EVI1) and myelodysplastic syndrome 1 (MDS1) are located at the center of this region, and their DNA copy number increases are associated with at least 5-fold increased RNA transcript levels in 83% and 98% of advanced ovarian cancers, respectively. Moreover, MDS1/EVI1 and EVI1 protein levels are increased in ovarian cancers and cancer cell lines. EVI1 and MDS1/EVI1 gene products increased cell proliferation, migration, and decreased transforming growth factor-β- mediated plasminogen activator inhibitor-1 promoter activity in ovarian epithelial cells. Intriguingly, the increases in EVI1 DNA copy number and MDS1/EVI1 transcripts are associated with improved patient outcomes, whereas EVI1 transcript levels are associated with a poor patient survival. Thus, the favorable patient prognosis associated with increased DNA copy number seems to be as a result of high-level expression of the fusion transcript MDS1/EVI1. Collectively, these studies suggest that MDS1/EVI1 and EVI1, previously implicated in acute myelogenous leukemia, contribute to the pathophysiology of epithelial ovarian cancer.

Original languageEnglish (US)
Pages (from-to)3074-3084
Number of pages11
JournalCancer Research
Volume67
Issue number7
DOIs
StatePublished - Apr 1 2007
Externally publishedYes

Fingerprint

Virus Integration
Myelodysplastic Syndromes
Ovarian Neoplasms
DNA
Bacterial Artificial Chromosomes
1-Phosphatidylinositol 4-Kinase
Comparative Genomic Hybridization
Plasminogen Activator Inhibitor 1
Transforming Growth Factors
Head and Neck Neoplasms
Acute Myeloid Leukemia
Cervix Uteri
Protein Kinase C
Cell Movement
Lung Neoplasms
Catalytic Domain
Chromosomes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. / Nanjundan, Meera; Nakayama, Yasuhisa; Kwai, Wa Cheng; Lahad, John; Liu, Jinsong; Lu, Karen; Kuo, Wen Lin; Smith-McCune, Karen; Fishman, David; Gray, Joe; Mills, Gordon.

In: Cancer Research, Vol. 67, No. 7, 01.04.2007, p. 3074-3084.

Research output: Contribution to journalArticle

Nanjundan, M, Nakayama, Y, Kwai, WC, Lahad, J, Liu, J, Lu, K, Kuo, WL, Smith-McCune, K, Fishman, D, Gray, J & Mills, G 2007, 'Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer', Cancer Research, vol. 67, no. 7, pp. 3074-3084. https://doi.org/10.1158/0008-5472.CAN-06-2366
Nanjundan, Meera ; Nakayama, Yasuhisa ; Kwai, Wa Cheng ; Lahad, John ; Liu, Jinsong ; Lu, Karen ; Kuo, Wen Lin ; Smith-McCune, Karen ; Fishman, David ; Gray, Joe ; Mills, Gordon. / Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. In: Cancer Research. 2007 ; Vol. 67, No. 7. pp. 3074-3084.
@article{641d44bcb0ae418da6fd8f435412424c,
title = "Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer",
abstract = "Increased copy number involving chromosome 3q26 is a frequent and early event in cancers of the ovary, lung, head and neck, cervix, and BRCA1 positive and basal breast cancers. The p110α catalytic subunit of phosphoinositide-3-kinase (PI3KCA) and protein kinase Cι (PKCι) have previously been shown as functionally deregulated by 3q copy number increase. High-resolution array comparative genomic hybridization of 235 high-grade serous epithelial ovarian cancers using contiguous bacterial artificial chromosomes across 3q26 delineated an ∼2 Mb-wide region at 3q26.2 encompassing PDCD10 to MYNN (chr3:168722613-170908630). Ecotropic viral integration site-1 (EVI1) and myelodysplastic syndrome 1 (MDS1) are located at the center of this region, and their DNA copy number increases are associated with at least 5-fold increased RNA transcript levels in 83{\%} and 98{\%} of advanced ovarian cancers, respectively. Moreover, MDS1/EVI1 and EVI1 protein levels are increased in ovarian cancers and cancer cell lines. EVI1 and MDS1/EVI1 gene products increased cell proliferation, migration, and decreased transforming growth factor-β- mediated plasminogen activator inhibitor-1 promoter activity in ovarian epithelial cells. Intriguingly, the increases in EVI1 DNA copy number and MDS1/EVI1 transcripts are associated with improved patient outcomes, whereas EVI1 transcript levels are associated with a poor patient survival. Thus, the favorable patient prognosis associated with increased DNA copy number seems to be as a result of high-level expression of the fusion transcript MDS1/EVI1. Collectively, these studies suggest that MDS1/EVI1 and EVI1, previously implicated in acute myelogenous leukemia, contribute to the pathophysiology of epithelial ovarian cancer.",
author = "Meera Nanjundan and Yasuhisa Nakayama and Kwai, {Wa Cheng} and John Lahad and Jinsong Liu and Karen Lu and Kuo, {Wen Lin} and Karen Smith-McCune and David Fishman and Joe Gray and Gordon Mills",
year = "2007",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-06-2366",
language = "English (US)",
volume = "67",
pages = "3074--3084",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer

AU - Nanjundan, Meera

AU - Nakayama, Yasuhisa

AU - Kwai, Wa Cheng

AU - Lahad, John

AU - Liu, Jinsong

AU - Lu, Karen

AU - Kuo, Wen Lin

AU - Smith-McCune, Karen

AU - Fishman, David

AU - Gray, Joe

AU - Mills, Gordon

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Increased copy number involving chromosome 3q26 is a frequent and early event in cancers of the ovary, lung, head and neck, cervix, and BRCA1 positive and basal breast cancers. The p110α catalytic subunit of phosphoinositide-3-kinase (PI3KCA) and protein kinase Cι (PKCι) have previously been shown as functionally deregulated by 3q copy number increase. High-resolution array comparative genomic hybridization of 235 high-grade serous epithelial ovarian cancers using contiguous bacterial artificial chromosomes across 3q26 delineated an ∼2 Mb-wide region at 3q26.2 encompassing PDCD10 to MYNN (chr3:168722613-170908630). Ecotropic viral integration site-1 (EVI1) and myelodysplastic syndrome 1 (MDS1) are located at the center of this region, and their DNA copy number increases are associated with at least 5-fold increased RNA transcript levels in 83% and 98% of advanced ovarian cancers, respectively. Moreover, MDS1/EVI1 and EVI1 protein levels are increased in ovarian cancers and cancer cell lines. EVI1 and MDS1/EVI1 gene products increased cell proliferation, migration, and decreased transforming growth factor-β- mediated plasminogen activator inhibitor-1 promoter activity in ovarian epithelial cells. Intriguingly, the increases in EVI1 DNA copy number and MDS1/EVI1 transcripts are associated with improved patient outcomes, whereas EVI1 transcript levels are associated with a poor patient survival. Thus, the favorable patient prognosis associated with increased DNA copy number seems to be as a result of high-level expression of the fusion transcript MDS1/EVI1. Collectively, these studies suggest that MDS1/EVI1 and EVI1, previously implicated in acute myelogenous leukemia, contribute to the pathophysiology of epithelial ovarian cancer.

AB - Increased copy number involving chromosome 3q26 is a frequent and early event in cancers of the ovary, lung, head and neck, cervix, and BRCA1 positive and basal breast cancers. The p110α catalytic subunit of phosphoinositide-3-kinase (PI3KCA) and protein kinase Cι (PKCι) have previously been shown as functionally deregulated by 3q copy number increase. High-resolution array comparative genomic hybridization of 235 high-grade serous epithelial ovarian cancers using contiguous bacterial artificial chromosomes across 3q26 delineated an ∼2 Mb-wide region at 3q26.2 encompassing PDCD10 to MYNN (chr3:168722613-170908630). Ecotropic viral integration site-1 (EVI1) and myelodysplastic syndrome 1 (MDS1) are located at the center of this region, and their DNA copy number increases are associated with at least 5-fold increased RNA transcript levels in 83% and 98% of advanced ovarian cancers, respectively. Moreover, MDS1/EVI1 and EVI1 protein levels are increased in ovarian cancers and cancer cell lines. EVI1 and MDS1/EVI1 gene products increased cell proliferation, migration, and decreased transforming growth factor-β- mediated plasminogen activator inhibitor-1 promoter activity in ovarian epithelial cells. Intriguingly, the increases in EVI1 DNA copy number and MDS1/EVI1 transcripts are associated with improved patient outcomes, whereas EVI1 transcript levels are associated with a poor patient survival. Thus, the favorable patient prognosis associated with increased DNA copy number seems to be as a result of high-level expression of the fusion transcript MDS1/EVI1. Collectively, these studies suggest that MDS1/EVI1 and EVI1, previously implicated in acute myelogenous leukemia, contribute to the pathophysiology of epithelial ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=34248219165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248219165&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-2366

DO - 10.1158/0008-5472.CAN-06-2366

M3 - Article

VL - 67

SP - 3074

EP - 3084

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -